Aptargroup, Inc.ATR

AptarGroup’s Q1 2026 revenue landed at $982.9 million, a figure that sounds healthier than the $222.5 million in cash and equivalents sitting on its balance sheet. The company’s inventory also grew by $16.9 million in the quarter, a detail that doesn’t quite square with its sustainability-themed press releases about reloadable airless dispensers. The gap between polished platform stories and the balance sheet’s actual contents is, at this point, a feature, not a bug.

Aptar isn’t just a pump and valve maker-it’s a business with three operating segments: Pharma, Beauty, and Food + Beverage. The Pharma division just secured MHRA GMP certification at Nanopharm, a credential that sounds impressive until you note that net income for the quarter was $72.7 million. The Beauty segment, meanwhile, is peddling ‘NeoDropper Autoload’ technology with Dermalogica, an innovation so targeted it feels like the company is trying to convince the world that skincare dosing is the next frontier of consumer demand. Sustainability wins, like a 2026 DIELINE Award for reloadable airless packaging with Clarins, make for great headlines, but the filing shows operating income of $107.5 million against $105.1 million in R&D spend-a tightrope walk, not a runway.

The 10-Q filing for the quarter ending 31 March 2026 reveals a company with $5.10 billion in assets and $2.63 billion in shareholders’ equity, but also highlights a few pressure points. Core Pharma sales dipped due to lower-margin products, while consumer healthcare revenue grew just 4% year-on-year. The F&F segment managed 3% growth, driven by prestige fragrance and colour cosmetics, but the filing concedes that tooling margins lagged versus Q1 2025. Cash from operations clocked in at $118.7 million, while capex gobbled $65.4 million, leaving little margin for error. Diluted EPS was $1.12 on 64.8 million shares, a figure that feels more pedestrian than the company’s sustainability theatre might suggest.

For a closer look at how Aptar’s equity story trades, the SEC filings and XBRL company facts are the primary rails. The company’s submissions JSON and companyfacts JSON on SEC EDGAR provide the raw data backbone, while the EDGAR index keeps track of the latest filings. If you’re hunting for colour beyond the numbers, the product news rail offers a steady drip of press releases about GMP certifications, auto-loading droppers, and sustainability awards, but these are marketing materials, not audited financial statements. The tension between the two is the story.

The filing evidence does not parse guidance, dividend policy, or share buybacks in this quarter. What it does show is a company with healthy headline revenue but thin cash conversion, high R&D burn relative to operating income, and a product narrative that outpaces its operating reality. The next catalyst would be a Q2 or H1 2026 update that either validates the sustainability and innovation narrative or forces the company to confront the arithmetic of its cash flows and margins.